Parallel Advisors, LLC Theravance Biopharma, Inc. Transaction History

Parallel Advisors, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$8.29 - $9.92 $646 - $773	78 Added 72.22%	186 $1,000
Q1 2024 May 06, 2024	SELL	$8.22 - $11.59 $12,338 - $17,396	-1,501 Reduced 93.29%	108 $0
Q4 2023 Feb 09, 2024	BUY	$8.58 - $11.4 $11,754 - $15,618	1,370 Added 573.22%	1,609 $18,000
Q3 2023 May 20, 2024	BUY	$8.38 - $10.44 $1,097 - $1,367	131 Added 121.3%	239 $2,000
Q3 2023 Nov 13, 2023	BUY	$8.38 - $10.44 $2,002 - $2,495	239 New	239 $2,000
Q3 2022 Nov 10, 2022	BUY	$8.39 - $10.22 $1,803 - $2,197	215 New	215 $2,000
Q1 2022 Apr 28, 2022	SELL	$8.33 - $12.96 $15,818 - $24,611	-1,899 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$7.42 - $11.05 $7,375 - $10,983	994 Added 109.83%	1,899 $21,000
Q3 2021 Nov 02, 2021	BUY	$6.77 - $14.41 $5,057 - $10,764	747 Added 472.78%	905 $7,000
Q2 2018 Jul 30, 2018	SELL	$22.06 - $25.52 $772 - $893	-35 Reduced 18.13%	158 $3,000
Q3 2017 Nov 15, 2017	BUY	$23.88 - $34.96 $4,608 - $6,747	193 New	193 $5,000
Q3 2017 Nov 14, 2017	SELL	$23.88 - $34.96 $4,608 - $6,747	-193 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	193	193 $6,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.